Article Information
History
- January 6, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- OE Babalola1,*,
- CO Bode2,
- AA Ajayi3,
- FM Alakaloko4,
- IE Akase5,
- E Otrofanowei6,
- OB Salu7,
- WL Adeyemo8,
- AO Ademuyiwa2 and
- S Omilabu7
- 1Department of Ophthalmology, Bingham University, Karu/Jos
- 2Department of Surgery, Faculty of Clinical Sciences, College of Medicine & Lagos University Teaching Hospital, Lagos, Nigeria
- 3Division of Hypertension and Clinical pharmacology, Keck Department of Medicine, Baylor College of Medicine Houston Texas, TX 77030 USA
- 4Department of Surgery, Lagos University Teaching Hospital, Lagos, Nigeria
- 5Department of Medicine, Lagos University Teaching Hospital
- 6Department of Medicine, Faculty of Clinical Sciences, College of Medicine/Lagos University Teaching Hospital
- 7Centre for Human and Zoonotic Virology, Central Research Laboratory/Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos
- 8Department of Oral and Maxillofacial Surgery, College of Medicine, University of Lagos
- ↵*CORRESPONDENCE
Prof Olufemi Emmanuel Babalola, Department of Ophthalmology, Bingham University, Karu/Jos, Nassarawa/Plateau state, Nigeria., Email: bablo57{at}gmail.com
Posted January 06, 2021.
Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos
